Showing 281 – 300 out of 345
Page 15 out of 18
| Tick | Thumbnails | Products | Price | Quantity | Action |
|---|---|---|---|---|---|
 |
Oncomine Acute Myeloid Leukemia (AML) Panel – Targeted NGS Solution for AML Research The Oncomine Acute Myeloid Leukaemia (AML) Panel is a cutting-edge genetic test that provides a full genomic picture of AML, helping doctors pinpoint key mutations, gene fusions, and copy number changes in genes known to drive the disease. Using advanced next-generation sequencing (NGS), this test delivers fast, precise results, even from limited or degraded sample, so patients get an accurate diagnosis and tailored treatment plans sooner. |
5.500,00 د.إ | |||
 |
5.500,00 د.إ | ||||
|
5.500,00 د.إ | ||||
|
Oncomine Comprehensive myeloid/ Leukemia Panel (DNA + RNA fusions) The Oncomine Comprehensive Myeloid/Leukemia Panel (DNA + RNA fusions) is a next-generation sequencing (NGS) assay designed for comprehensive genomic profiling of myeloid malignancies and leukemias. It simultaneously analyzes DNA and RNA to detect key mutations, copy number variations, and gene fusions across a broad range of clinically relevant genes. |
5.500,00 د.إ | |||
|
5.500,00 د.إ | ||||
 |
Oncomine MDS Panel – Comprehensive Genetic Testing for Myelodysplastic Syndromes The Oncomine Myelodysplastic Syndrome (MDS) Panel detects genetic mutations linked to MDS and blood cancers. Accurate, next-generation sequencing. Book your test today. |
5.500,00 د.إ | |||
|
5.500,00 د.إ | ||||
|
4.100,00 د.إ | ||||
|
Oncomine Myeloproliferative Neoplasm (MPN) Panel – Accurate NGS Testing for MPN Mutations The Oncomine Myeloproliferative Neoplasm (MPN) Panel is a cutting-edge genetic test that analyzes key mutations in JAK2, CALR, and MPL, the genes most commonly linked to myeloproliferative disorders. Using advanced next-generation sequencing (NGS), this test provides a highly accurate and efficient way to diagnose and classify MPNs, even when only small or degraded samples are available (as little as 10 ng of DNA or RNA). |
5.500,00 د.إ | |||
 |
Oncotype DX Breast Cancer Test – Personalized Risk Assessment & Treatment Guidance The Oncotype DX Breast Cancer (ML) Test is a genomic assay that analyzes the activity of 21 genes in a breast cancer tumor to predict the risk of recurrence and the potential benefit of chemotherapy. Designed for early-stage, hormone receptor-positive, HER2-negative breast cancer patients, it provides a Recurrence Score® result that helps guide personalized treatment decisions. Key benefits include reducing unnecessary chemotherapy, improving patient outcomes, and offering evidence-based insights backed by extensive clinical validation. |
35.000,00 د.إ | |||
 |
Outside Referrals (sendout Consultation – Histology and Cytology) Sample Type : Slides and Block(s)
Methodology : Microscopy
TAT : 21 Days |
4.450,00 د.إ | |||
|
1.520,00 د.إ | ||||
 |
Parvovirus IgG and IgM Abs Sample Type : Serum
Methodology : TBA
TAT : 10 Days |
950,00 د.إ | |||
 |
PCR FOR HLA B27 (EDTA) PCR for HLA-B27 (EDTA) is a molecular diagnostic test used to detect the HLA-B27 gene, which is strongly associated with autoimmune disorders like ankylosing spondylitis and other spondyloarthropathies. Utilizing Polymerase Chain Reaction (PCR) technology, this test offers high sensitivity and specificity, ensuring accurate and reliable results. |
2.400,00 د.إ | |||
|
PD-L1 (22C3) Dako CPS IHC Test – Accurate Immunohistochemistry for Cancer Diagnosis The PD-L1 (22C3) Dako CPS (IHC) test is an immunohistochemistry (IHC) assay designed to assess PD-L1 expression in tumor and immune cells using the Combined Positive Score (CPS). It is FDA-approved as a companion diagnostic for multiple cancer therapies, ensuring precise patient selection for immune checkpoint inhibitors. The test utilizes the 22C3 monoclonal antibody, providing high sensitivity and specificity in detecting PD-L1 expression. Its standardized scoring system (CPS) enhances reproducibility and clinical decision-making, making it a trusted tool for oncologists. The Dako platform ensures consistent, high-quality staining, supporting accurate and reliable results for personalized cancer treatment. |
3.500,00 د.إ | |||
|
3.200,00 د.إ | ||||
|
Phospholipase A2 Receptor Antibodies Sample Type : Serum
Methodology : Immunofluorescence
TAT : 21 Days |
1.850,00 د.إ | |||
|
Pneumococcal abs. (IgG) Vaccination status Sample Type : Serum
Methodology : EIA
TAT : 18 Days |
850,00 د.إ | |||
|
Pneumococcal antigen- urine Sample Type : Random Urine
Methodology : Immunochromatography
TAT : 14 Days |
550,00 د.إ | |||
|
PredictLife Test – Advanced DNA Health & Wellness Analysis for Personalized Insights PredictLife Test is a cutting-edge DNA-based health and longevity assessment that provides personalized insights into your genetic predispositions, lifestyle risks, and potential health outcomes. Using advanced AI and genomic analysis, it evaluates factors like disease risks, aging patterns, nutrition, and fitness optimization. |
3.200,00 د.إ |